- Home
- KNRX vs MDCX Comparison
KNRX vs MDCX Comparison
Compare KNRX & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
BUY
Current Price
$0.18
Company Overview
Basic Information| Metric | KNRX | MDCX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 10.9M |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | KNRX | MDCX |
|---|---|---|
| Price | $0.18 | $2.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $266.67 |
| AVG Volume (30 Days) | ★ 13.6M | 1.4M |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.08 |
| 52 Week High | $3.45 | $4.69 |
Technical Indicators
Market Signals| Indicator | KNRX | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 65.44 |
| Support Level | $0.15 | $0.26 |
| Resistance Level | $0.49 | $4.69 |
| Average True Range (ATR) | 0.02 | 0.33 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 26.07 | 52.67 |
Price Performance
Historical Comparison KNRX
MDCX
About KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.